Investor Presentaiton

Achieved breakthrough innovation Now Approved India's first indigenously developed CAR-T cell therapy, NexCAR19 granted marketing approval from CDSCO on October 12, 2023 Treatment eligible for Adult patients with relapsed or refractory B-cell lymphomas and leukemia in India. Multi-center Phase I/ II pivotal clinical trial, conducted with 60 patients; clinical data indicates ~70% overall response rate (ORR) Favorable balance of efficacy and toxicity with low grade CRS1; a significant improvement over other commercially approved CD19-directed CAR-T cell therapies Invested over 94 crores in ImmunoAct and further working towards enhancing the GMP facility to service more patients NexCAR19 (Actalycabtagene autoleucel) CAR-T Product MADE IN INDIA Combination of ImmunoAct R&D pipeline, technology and Laurus support in building manufacturing capabilities will accelerate our pursuit of next generation innovation in cell therapies and new drug discovery 1 CRS=cytokine release syndrome; CAR T-chimeric antigen receptor T cells 9 Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation